PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Gayle Jameson, RN, MSN, ACNP-BC, AOCN - Making Headway Toward Better Outcomes in Pancreatic Cancer: The Oncology Nurse as a Leader and Advocate for Patients in an Era of Advances in Care and Research
Go online to PeerView.com/USV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the understanding of the science of pancreatic cancer have led to improved outcomes for patients with this traditionally difficult-to-treat malignancy, along with greater opportunities for oncology nurses to partner with patients and members of their cancer team to implement new standards of care. This CNE-certified activity, presented by PeerView in collaboration with Let’s Win, an affiliate of the Lustgarten Foundation, will focus on effective management strategies with novel chemotherapy platforms, personalizing care with PARP and checkpoint inhibitors, and preparing for emerging multimodal approaches, such as tumor-treating fields (TTFields) therapy. Pancreatic cancer nurse expert, Gayle Jameson, will provide practical guidance on recognizing and managing adverse events associated with established and emerging treatments, counseling patients and their families on personalizing treatment plans, and addressing issues related to clinical trial enrollment. Upon completion of this activity, participants will be able to: Review the latest efficacy and safety data on available and emerging treatments for pancreatic cancer, including novel chemotherapy platforms, PARP inhibitors, targeted agents directed against molecular features/mutations, among others, Counsel patients on the clinical and potential use of novel treatments for pancreatic cancer, such as chemotherapy platforms for the metastatic setting, PARP inhibitors for the front-line maintenance setting, and the option of enrolling in clinical trials, Plan effective strategies to manage adverse events associated with established and emerging therapies for pancreatic cancer.